Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes. METHODS: In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks. The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis after randomization. Secondary end points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressure, and mean daily bolus dose of insulin. RESULTS: A significantly larger proportion of patients in the sotagliflozin group than in the placebo group achieved the primary end point (200 of 699 patients [28.6%] vs. 107 of 703 [15.2%], P<0.001). The least-squares mean change from baseline was significantly greater in the sotagliflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points), weight (-2.98 kg), systolic blood pressure (-3.5 mm Hg), and mean daily bolus dose of insulin (-2.8 units per day) (P≤0.002 for all comparisons). The rate of severe hypoglycemia was similar in the sotagliflozin group and the placebo group (3.0% [21 patients] and 2.4% [17], respectively). The rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter) or below was significantly lower in the sotagliflozin group than in the placebo group. The rate of diabetic ketoacidosis was higher in the sotagliflozin group than in the placebo group (3.0% [21 patients] and 0.6% [4], respectively). CONCLUSIONS: Among patients with type 1 diabetes who were receiving insulin, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe hypoglycemia or diabetic ketoacidosis was larger in the group that received sotagliflozin than in the placebo group. However, the rate of diabetic ketoacidosis was higher in the sotagliflozin group. (Funded by Lexicon Pharmaceuticals; inTandem3 ClinicalTrials.gov number, NCT02531035 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Use of these processes may have contributed to the lower rates of ketoacidosis seen in some of the studies of these agents for adjunctive glycemic management in people with type 1 diabetes (314-316) compared with those that did not include preventative strategies (310,317).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [316]
In the citing paper
“Information on the safety and efficacy of combining MRAs with SGLT2 inhibitors in CKD is limited as only ∼4% of FIDELIO-DKD, ∼8% of FIGARO-DKD, ∼5% of DAPA-CKD, and no CREDENCE participants were prescribed such a combination.153,718,719,721”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“FIDELIO-DKD and FIGARO-DKD excluded patients with a potassium of >4.8 mmol/L, as MRAs cause hyperkalaemia.718,719”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“The placebo-controlled FIDELIO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease) and FIGARO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease) trials demonstrated for the non-steroidal MRA finerenone that these effects translate into reduced risk of kid”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationSGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 560
Weissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050
Imperatore, G., Boyle, J. P., Thompson, T. J., Case, D., Dabelea, D., Hamman, R. F., Lawrence, J. M., Liese, A. D., Liu, L. L., Mayer-Davis, E. J., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0669 · Cited by 484
8. Pharmacologic Approaches to Glycemic Treatment
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s011 · Cited by 458
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
Research works printed but not linked: 1
- Lyons SK, Diabetes Care
Cited by
Items 201–300 of 421
Double Diabetes: A Growing Problem Requiring Solutions
Popovic, D. S., & Παπάνας, Ν. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1392-0590 · Cited by 14
Powell, D. R., Revelli, J., Doree, D. D., DaCosta, C. M., Desai, U., Shadoan, M. K., Rodriguez, L., Mullens, M., Yang, Q. M., Ding, Z., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s322083 · Cited by 16
Recent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 17
Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes
Tosur, M., REDONDO, M. J., & Lyons, S. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1041-1 · Cited by 15
Diabetes: the place of new therapies
Dhatariya, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818807599 · Cited by 14
Kaku, K., Isaka, H., Sakatani, T., & Toyoshima, J. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13181 · Cited by 14
The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
Gillard, P., Schnell, O., & Groop, P. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108462 · Cited by 14
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
Rendell, M. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s144556 · Cited by 14
“Lexicon chose the 400 mg dose for the final pivotal study (InTandem 3), enrolling 1,402 patients with type 1 diabetes on either insulin pump or multiple daily insulin injections.(45) The least-squares mean change from baseline was significantly greater in the sotagliflozin group than in the placebo group for HbA1c (di…”
BackgroundPopovic, D. S., Karakasis, P., Koufakis, T., Fragakis, N., Παπάνας, Ν., Mitrović, M., Gouveri, E., & Patoulias, D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155791 · Cited by 15
Patel, K. S., & Carbone, A. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019859323 · Cited by 15
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure
Cavallari, I., Crispino, S. P., Segreti, A., Ussia, G. P., & Grigioni, F. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00601-9 · Cited by 15
Milder, T. Y., STOCKER, S. L., Samocha‐Bonet, D., Day, R. O., & Greenfield, J. R. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02732-y · Cited by 15
Cebada, A. B., Nattero‐Chávez, L., Díaz, S. A., Escobar-Morreale, H. F., & Luque‐Ramírez, M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0316 · Cited by 13
Adjunctive Therapies to Optimize Closed-loop Glucose Control
Srinivasan, S., Ekhlaspour, L., & Cengiz, E. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211032701 · Cited by 14
New therapies towards a better glycemic control in youths with type 1 diabetes
Cardona‐Hernandez, R., Dovč, K., Biester, T., Ekhlaspour, L., Macedoni, M., Tauschmann, M., & Mameli, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106882 · Cited by 13
Bantounou, M. A., Sardellis, P., Plascevic, J., Mahmood, R., Kaczmarek, J., Boada, D. B., Thuemmler, R. J., & Philip, S. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15036 · Cited by 14
Sodium‐glucose co‐transporters and diabetic nephropathy: Is there a link with toll‐like receptors?
Jigheh, Z. A., Haghjo, A. G., Argani, H., & Sanajou, D. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13261 · Cited by 12
Chiba, K., Nomoto, H., Nakamura, A., Cho, K. Y., Yamashita, K., Shibayama, Y., Miya, A., Kameda, H., Kurihara, Y., Aoki, S., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13335 · Cited by 12
Danne, T., Joish, V. N., Afonso, M., Banks, P. L., Sawhney, S., Lapuerta, P., Davies, M. J., Buse, J. B., Lin, D., Reaney, M. D., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0068 · Cited by 12
Self-citationRodbard, H. W., Giaccari, A., Cariou, B., Garg, S. K., Davies, M. J., Seth, K., & Sawhney, S. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/1479164121995928 · Cited by 12
Self-citationZhou, F.-F., Du, N., Zhou, L., Wang, C., Ren, H., & Sun, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.968478 · Cited by 11
“Inclusion criteria: (1) The included articles were English reports of completed clinical randomized controlled trials that focused on the efficacy and safety of sotagliflozin in DM treatment, (2) the included articles were RCTs with sotagliflozin involved in phases II or III; (3) the included articles mentioned the re…”
BackgroundInfluentialSodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Hropot, T., Battelino, T., & Dovč, K. (2022) · Hormone Research in Paediatrics · doi:10.1159/000527653 · Cited by 12
“The inTandem1−3 clinical trials studied the effects of sotagliflozin in adults with type 1 diabetes [35– 37].”
Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes
Biester, T., Kordonouri, O., & Danne, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13659 · Cited by 13
“2% in placebo).(25) In subjects on sotagliflozin less hypoglycemia <3.”
BackgroundSelf-citationSpexin-based galanin receptor 2 agonist improves renal injury in mice with type 2 diabetes
Joo, J., Park, B. Y., Yoon, S. G., Park, H., Yoo, J. A., Ghee, J. Y., Cha, D. R., Seong, J. Y., & Kang, Y. S. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2263067 · Cited by 13
“diabetic drugs, including sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in addition to RAAS blockade, are effective against diabetic nephropathy and reduce cardiovascular-related events in patients with diabetes (Zinman et al. 2015; Garg et al. 2017; Neal et al. 2017; Mahaffey et al.…”
BackgroundLin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Enterocyte HKDC1 Modulates Intestinal Glucose Absorption in Male Mice Fed a High-fat Diet
Zapater, J. L., Wicksteed, B. L., & Layden, B. T. (2022) · Endocrinology · doi:10.1210/endocr/bqac050 · Cited by 11
“Currently, there are only a few medications designed to prevent intestinal glucose uptake, and their usage is limited due to gastrointestinal side effects (18-20).”
BackgroundSGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Ma, Y., Zhao, Q., Peng, H., Nalisa, D. L., Shan, P., & Jiang, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805098 · Cited by 11
“In addition, compared with baseline measurements, patients in the 400 mg sotagliflozin group had a 2.98 kg weight reduction [28].”
MethodInfluentialPerkins, B. A., Soleymanlou, N., Rosenstock, J., Skyler, J. S., Laffel, L. M., Liesenfeld, K., Neubacher, D., Riggs, M. M., Johnston, C., Eudy‐Byrne, R. J., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13945 · Cited by 11
Nardone, M., Kugathasan, L., Sridhar, V. S., Dutta, P., Campbell, D. J. T., Layton, A. T., Perkins, B. A., Barbour, S. J., Lam, T. K. T., Levin, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000641 · Cited by 11
A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor
Siddiqui, Z., Rasouli, N., Felder, E., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000760 · Cited by 10
Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2
Scheen, A. J. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30005-1 · Cited by 15
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes
Rendell, M. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1537779 · Cited by 10
“Lexicon chose the 400 mg dose for a final pivotal study (Tandem 3), enrolling 1402 patients with type 1 diabetes on either insulin pump or injections [25].”
BackgroundSGLT inhibitors for people with type 1 diabetes
Llano, A., McKay, G., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2222 · Cited by 10
Aberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
“Sotagliflozin 6 3236 1912 1324 2015 [80], 2017 [81], 2018 (2×) [82,83], 2019 [84], 2021 [85]”
BackgroundSodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
Moady, G., Gal, T. B., & Atar, S. (2023) · Life · doi:10.3390/life13061256 · Cited by 12
“Of them, three had genitourinary infections, four had driveline infections (DLI), and two patients had limb amputations with no episodes of diabetic ketoacidosis (DKA) or renal function deterioration, and with no change in weight or diuretic dose.”
BackgroundInfluentialSotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure
Long, A. M., & Salvo, M. C. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231211179 · Cited by 10
“21-23 The manufacturers attempted to obtain the same indication in the United States in 2019; however, sota-gliflozin was not approved by the FDA.”
Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes
Isaacs, D. M., Yager, S., Parker, M., Wolfe, L., Luxenburg, J., & Lekic, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018816728 · Cited by 10
Nubiola, A., Ternianov, A., & Remolins, I. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.09.003 · Cited by 10
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
“The safety and glycemic efficacy of SGLT2 inhibition in T1D patients was evaluated in the DEPICT [91–94], EASE [95], and inTandem [96–99] trials, each clearly demonstrating reductions in HbA1c and body weight after 24–52 weeks of treat-ment.”
Maddaloni, E., Naciu, A. M., Mignogna, C., Galiero, R., Amendolara, R., Fogolari, M., Satta, C., Serafini, C., Angeletti, S., Cavallo, M. G., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15469 · Cited by 11
“15,16 Based on these considerations, we hypothesized that combination therapy with inhibitors of dipeptidyl-peptidease-4 (DPP-4) plus SGLT2 inhibitors, may be an alternative therapeutic strategy to basal insulin in people with LADA who still have some detectable endogenous insulin production.”
BackgroundSelf-citationTran, B. A., White, R. T., Bullers, K., & Cornelio, C. K. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241261040 · Cited by 9
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
“Consistent with this trend, guidelines by the Brazilian Diabetes Society already recommend that semaglutide should be considered in patients with T2D and CKD with eGFR > 25 mL/minute/1.73 m² and uACR > 100 mg/g to reduce renal outcomes in association with SGLT2i[174].”
InfluentialThe double burden: Navigating type 1 diabetes and obesity
Steenackers, N., Feldman, A., Mathieu, C., Rosen, J., Söderberg, J. A. E., Al‐Ozairi, E., le Roux, C. W., & der Schueren, B. V. (2024) · Clinical Obesity · doi:10.1111/cob.12645 · Cited by 10
“41 Several studies have investigated the efficacy and safety of these adjunctive therapies, 42 – 44 but there remains an unmet need for people living with type 1 diabetes.”
BackgroundSGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
Chen, H., Birnbaum, Y., Ye, R., Yang, H., Bajaj, M., & Ye, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07243-6 · Cited by 9
Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?
Biester, T., Kordonouri, O., & Danne, T. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818763247 · Cited by 10
Self-citationHuang, Y., Jiang, Z., & Wei, Y. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0034 · Cited by 10
Expanding the Use of SGLT2i in Diabetes Beyond Type 2
Giaccari, A. (2023) · Diabetes Care · doi:10.2337/dci23-0065 · Cited by 9
Guo, Y., Lin, C., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112899 · Cited by 9
Latent autoimmune diabetes in youth
Sun, Q., Yang, M., Jing, Y., Meng, L., Zhang, C., Ruan, J., & Wu, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691377 · Cited by 9
STOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 11
Tsur, A., Leibowitz, G., Cohen, M. J., Cahn, A., & Pollack, R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16545 · Cited by 9
Gliflozine – in Zukunft Kardioprotektiva?
Rauch‐Kröhnert, U., & Landmesser, U. (2021) · Der Internist · doi:10.1007/s00108-021-01083-0 · Cited by 8
Efficacy and safety of sotagliflozin in treating diabetes type 1
Rendell, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1414801 · Cited by 11
“Lexicon chose the 400 mg dose for a final pivotal study (Tandem 3), enrolling 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) [27].”
BackgroundInfluentialSGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Gill, A., Gray, S. P., Jandeleit-Dahm, K. A. M., & Watson, A. M. D. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180417121246 · Cited by 9
Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes
Urakami, T., Yoshida, K., & Suzuki, J. (2023) · Internal Medicine · doi:10.2169/internalmedicine.9632-22 · Cited by 9
“Regarding laboratory data, the mean levels of FPG and HbA1c were 140.8±9.1 (126-162) mg/dL and 8.2% ±0.6% (7.3-9.5%), respectively.”
BackgroundResultInfluentialSaha, S., & Saha, S. (2020) · PubMed Central · Cited by 11
Abdel‐Rahman, S. M., Al-Shiab, R., Shah, E., Güldan, M., Ak, A. B., Yilmaz, Z. Y., Fidan, D. G., Özbek, L., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70506 · Cited by 7
“9 However, safety concerns remain, particularly gastrointestinal adverse effects with GLP-1RAs and an increased risk of diabetic ketoacidosis (DKA) with SGLT2-based therapies 10 Although prior systematic reviews have examined these drugs, the evidence base has expanded substantially in recent years…”
Khayari, A. E., Hakam, S. M., Malka, G., Rochette, L., & Fatimy, R. E. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101174 · Cited by 8
Cottam, A., Cottam, D. R., Roslin, M. S., & Surve, A. (2024) · JSLS Journal of the Society of Laparoscopic & Robotic Surgeons · doi:10.4293/jsls.2023.00051 · Cited by 7
SGLT inhibition in T1DM — definite benefit with manageable risk
Ferrannini, E., & Solini, A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.139 · Cited by 7
Lim, S. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13696 · Cited by 9
“In another study with patients with T1D, adding sotagliflozin, an SGLT2/1 co-inhibitor, to insulin reduced HbA1c level, body weight and blood pressure.(32) The overall hypoglycaemia rate did not differ between the sotagliflozin and placebo groups.”
BackgroundAbiru, N., Nakatsuji, Y., Noguchi, M., & Tsuboi, K. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2193393 · Cited by 7
Nakamura, Y., Horie, I., Kitamura, T., Kusunoki, Y., Nishida, K., Yamamoto, A., Hirota, Y., Fukui, T., Maeda, Y., Minami, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15458 · Cited by 8
Wang, W., Zhang, L., Pei, X., Pan, Q., & Guo, L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14092 · Cited by 7
Using adjuvant pharmacotherapy in the treatment of type 1 diabetes
Sjöholm, Å. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939679 · Cited by 7
“In the larger multicenter phase 3 inTandem 3 study [47], the proportion of patients with HbA1c < 53 mmol/mol, no severe hypoglycemia, and no DKA was significantly higher in”
BackgroundPopovic, D. S., Patoulias, D., Koufakis, T., Karakasis, P., & Παπάνας, Ν. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01657-9 · Cited by 6
“Finally, inTandem3 trial, enrolling 1402 adults with T1D and HbA 1c of 7.0–11.0%, demonstrated a 0.46% reduction in HbA 1c, and a 2.98 kg reduction in body weight in participants treated with 400 mg sotagliflozin, versus those receiving placebo, after 24 weeks of treatment [12].”
InfluentialWang, S., Zhang, Y., Balati, A., Li, B., Dai, L., & Yu, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf016 · Cited by 7
Rajab, A. M., Pearson, S. M., & Ajjan, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16332 · Cited by 7
“82,86 – 88 Importantly, the improvement in HbA1c with SGLT2i did not occur at the expense of increased hypoglycaemia, 89,90 representing a clear advantage over increased insulin doses for treating hyperglycaemia.”
Sharma, A., Baig, S. A., Thayakaran, R., Rengarajan, L. N., Philip, N. C., Abraham, A. A., Manta, A., Narendran, P., Dhatariya, K., Umpierrez, G. E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70098 · Cited by 7
Liu, Y., Yang, S., Jiang, A., Zou, D., Chen, Z., & Su, N. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1453067 · Cited by 9
Registration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251334993 · Cited by 7
Self-citationRegistration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0130 · Cited by 6
Self-citationSodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus
Li, N., Chen, R., & Liu, K. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00949-9 · Cited by 6
Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus
Vitale, R. J., & Laffel, L. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.05.001 · Cited by 7
Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel, S., Galderisi, A., Patel, N. S., CARRIA, L. R., Tamborlane, W. V., & Sherr, J. L. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0356 · Cited by 6
An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes
Chatzopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1793961 · Cited by 7
Kharve, K., Engley, A. S., Paine, M. F., & Sprowl, J. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040447 · Cited by 5
“…along with a reversed A dose-limiting adverse event associated with sotagliflozin is diarrhea, which results from carbohydrate accumulation in the gastrointestinal tract, along with a reversed osmotic flow of water following the loss of SGLT1 activity within enterocytes [24]. staining intensity.”
BackgroundNoninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
Zhang, Z., Li, Y., Gu, H. F., & Li, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118837 · Cited by 5
Fatima, E., Irfan, H., Fatima, F., Jain, J., Rehman, O. U., Sehar, A., Ahmad, B., Kumari, S., & Akilimali, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003357 · Cited by 6
“Though the risk is more than placebo-treated individuals but less than values reported for canagliflozin [47] .”
InfluentialJENDLE, J. H., Ampudia‐Blasco, F. J., Füchtenbusch, M., & Pozzilli, P. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.12 · Cited by 6
“DKA occurred more often in the sotagliflozin group.(7,8) Results from the inTandem1 and -2 were similar.”
ResultSelf-citationBiester, T., & Danne, T. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0268 · Cited by 5
Self-citationThe anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
Kugathasan, L., Dubrofsky, L., Advani, A., & Cherney, D. Z. I. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2159810 · Cited by 5
Borges, R. D. S., Almeida, G. D. O., Alves, V. F. C., Nienkotter, T. F., Bertoli, E. D., & Silva, A. C. S. E. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01818-2 · Cited by 5
“It increases glucosuria by inhibiting SGLT2 in the renal proximal tubule, and also delays absorption of post-prandial glucose via SGLT1 blockade in the gastrointestinal tract [13–18].”
Wörmeyer, L., Nortmann, O., Hamacher, A. B., Uhlemeyer, C., Belgardt, B., Eberhard, D., Mayatepek, E., Meißner, T., Lammert, E., & Welters, A. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2236-8625 · Cited by 6
“Among insulin-treated adult individuals with type 1 diabetes, worldwide only 15 % achieve HbA1c levels below 7 % without episodes of severe hypoglycemia or diabetic ke-toacidosis [7].”
Kurozumi, A., Okada, Y., & Tanaka, Y. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0577 · Cited by 5
“Several clinical trials have been con‐ ducted to define the indications for use of sodiumglucose transporter 2 inhibitor (SGLT2-I) in T1DM [1-3].”
BackgroundA Comprehensive Guide to Sodium Glucose Cotransport Inhibitors
Cunningham, C., Jabri, A., Alhuneafat, L., & Aneja, A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101817 · Cited by 7
Silva, V. B., Fonseca, L., Duarte, D. B., Puga, F. M., Assuncao, G., Garrido, S., Teixeira, S., Vilaverde, J., & Cardoso, M. H. (2023) · Endocrine Regulations · doi:10.2478/enr-2023-0018 · Cited by 5
van Laar, A., Gallardo‐Nuell, L., Pazmiño, S., Visser, M. M., Mertens, A. C., Vangoitsenhoven, R., Gillard, P., Al‐Ozairi, E., le Roux, C. W., Rosen, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103589 · Cited by 4
Nardone, M., Moedt, E., Heerspink, H. J. L., Davies, M. J., Girard, M., Cherney, D. Z. I., & Muskiet, M. H. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70520 · Cited by 4
Self-citationTentolouris, A., Koufakis, T., & Fousteris, E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00693-9 · Cited by 5
“In the phase 3, inTandem3 RCT, 1,402 adults with T1DM receiving insulin therapy were randomized to sotagliflozin (dual SGLT1/2 inhibitor) 400 mg/day or placebo for 24 weeks [106].”
XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions
Sun, Y., Zhang, Y., Zhang, J., Chen, Y. E., Jin, J., Zhang, K., Mou, H., Liang, X., & Xu, J. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01203-x · Cited by 4
“Several SGLT inhibitor drugs, including Empagliflozin, Dapagliflozin and Sotagliflozin, have gained major agencies’ approval for clinical applications [42–44].”
BackgroundCurovic, V. R., STOUGAARD, E. B., & Hansen, T. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16007 · Cited by 4
Lei, Y., Yao, S., Wang, Z., Tu, Q., Yuan, Z., & Jiang, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1506652 · Cited by 4
Economic Impact of Diabetic Ketoacidosis in the United States
Panjwani, Q., & Bindal, A. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390832 · Cited by 4
SGLT 2 inhibitors in Type 1 diabetes: is this the future?
Herring, R. A., & Russell-Jones, D. L. (2018) · Diabetic Medicine · doi:10.1111/dme.13791 · Cited by 4
Hamaguchi, M., Hashimoto, Y., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Ushigome, E., Yamazaki, M., et al. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211040539 · Cited by 4
Small steps forward: Adjunctive therapy for T1D
Bloomgarden, Z. T., & Schatz, D. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13326 · Cited by 4
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials
Min, T., & Bain, S. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2188191 · Cited by 4
“6%), as was the frequency of dehydration and genital infections [52].”
Background
Metadata
- Authors
- Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., Danne, T., McGuire, D. K., Kushner, J. A., Peters, A., & Strumph, P.
- Affiliations
- University of Southern California (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-14
- Volume
- 377
- Issue
- 24
- Pages
- 2337-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2755899227
- Cited by
- 417
- References
- 34
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 38 · 2023: 36 · 2022: 32 · 2021: 41 · 2020: 57 · 2019: 72 · 2018: 64 · 2017: 10
- FWCI
- 43.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Wayne State University
- Alere
- University of Dundee
- Massachusetts Medical Society
- Intarcia Therapeutics
- Bigfoot Biomedical
- MannKind Corporation
- Dexcom
- AstraZeneca HealthCare Foundation
- University of Leicester
- Eisai
- Novo Nordisk
- Servier
- Mitsubishi Tanabe Pharma Corporation
- Esperion Therapeutics
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, SGLT2 inhibitors, insulin therapy, glycemic control, HbA1c, hypoglycemia, diabetic ketoacidosis, weight loss, systolic blood pressure, insulin dose reduction, combination therapy, drug safety and efficacy, insulin pump, insulin injection
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Least-Squares Analysis, Diabetic Ketoacidosis, Sodium-Glucose Transport Proteins, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.